NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis.
- FLASCO
- August 8, 2016
- News
NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. These NCCN Guidelines are currently available as Version 1.2016.
- “Clinical Breast Exam” was changed to “Clinical Encounter” with the footnote stating, “Clinical encounter should encompass ongoing risk assessment, risk reduction counseling, as well as a clinical breast exam.” (BSCR-1)
- “Consider tomosynthesis” is a new bullet under annual screening mammogram. (BSCR-1).The panel has noted on page BSCR-A, (page 1 of 2 on Breast Screening Considerations) that “Multiple studies show a combined use of digital mammography and tomosynthesis appears to improve cancer detection and decreased call back rates. Of note, most studies used double the dose of radiation. The radiation dose can be minimized by synthetic 2-D reconstruction.”
- For patients with prior thoracic radiation, the panel recommends annual screening mammogram and annual MRI to begin 8-10 y after RT but not prior to age 25 y. (BSCR-3)
- The panel has provided guidelines for followup of LCIS based on whether it is non-concordant with imaging, concordant with imaging, or pleomorphic LCIS.(BSCR-8)
- New guidelines on screening and followup for breast pain have been included. (BSCR-16)
- On page BSCR-A, page 1 of 2, the panel has noted that “In high-risk settings based on current evidence and considering the FDA warning (Gadolinium-based contrast agents) we continue to recommend annual MRI in these select populations.”
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
